NUVL - Leadership updates

New Drug Application for neladalkib in TKI pre-treated advanced ALK-positive NSCLC accepted for filing with Priority Review by the FDA with PDUFA target action date of November 27, 2026Veteran biopharmaceutical executive, Georg Pirmin Meyer, M.D., joins as Chief International Officer to lead Nuvalent's global expansion strategyCAMBRIDGE, Mass., May 27, 2026 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the acceptance of its New Drug Application (NDA) for neladalkib for filing by the U.S. Food and Drug Administration (FDA). The FDA has gra

CAMBRIDGE, Mass., Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Ron Squarer to its Board of Directors. "We welcome Ron to our Board of Directors, where his personal dedication to advancing oncology therapeutics, demonstrated success in evolving research and development organizations to fully integrated businesses, and proven global commercial acumen will strengthen and sharpen our pre-launch

Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of 2025 Initiated ALKAZAR Phase 3 randomized, controlled trial of neladalkib for front-line ALK-positive NSCLC Topline pivotal data for neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC expected by year-end 2025 Preliminary data for neladalkib in patients with ALK-positive solid tumors beyond NSCLC to be presented at the ESMO Congress 2025 Jason Waters, MBA, promoted to Senior Vice President, Commercial CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical

CAMBRIDGE, Mass., June 18, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Christy Oliger to its Board of Directors. "Christy's proven success in delivering new therapies to patients living with cancer strengthens our Board as we evolve from a development-stage company toward potential commercialization," said James Porter, Ph.D., Chief Executive Officer at Nuvalent. "We welcome her deep expertise and

CAMBRIDGE, Mass., Dec. 9, 2024 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Grant Bogle to its Board of Directors. "Grant's demonstrated success in leading the growth and evolution of oncology biotechnology companies augments our Board as we work towards a potential first approval from our pipeline of novel kinase inhibitors in 2026," said James Porter, Ph.D., Chief Executive Officer at Nuvalent. "We wel

CAMBRIDGE, Mass., Oct. 6, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Michael L. Meyers, M.D., Ph.D., to its Board of Directors. An experienced drug developer and medical oncologist who has contributed to the successful development and commercialization of multiple new therapies for patients with cancer, Dr. Meyers has served as a Senior Clinical Advisor to Nuvalent since 2020. "We look forward to

Veteran Biotech Executive with Broad Oncology Perspective to Lead Nuvalent Board as Company Advances its Pipeline of Precisely Targeted Therapies CAMBRIDGE, Mass., March 31, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical stage biopharmaceutical company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics, as Chair of its Board of Directors. "I am excited to join the Nuvalent Board of Directors and have been impressed

NVL-655 IND cleared by FDA, supporting planned initiation of ALKOVE-1 Phase 1/2 clinical trial in patients with ALK-positive NSCLC and other solid tumors in second quarter of 2022 Enrollment ongoing in ARROS-1 trial of NVL-520 for advanced ROS1-positive NSCLC and other solid tumors Discovery pipeline continues to advance toward two development candidate nominations in 2022 CAMBRIDGE, Mass., March 29, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today reported pipeline and business progress and fourth quarter and full year 2021 financial results.

CAMBRIDGE, Mass., Feb. 3, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Emily Drabant Conley, Ph.D., Chief Executive Officer of Federation Bio, to its Board of Directors. "I'm impressed by Nuvalent's focus on compelling science and only advancing opportunities with best-in-class potential, both of which I believe position the company to deliver on their goal of new therapies that may help physicians and their patients stay one st